Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: A systematic review of published studies

Tumori

Volumn 96, Issue 3, 2010, Pages 385-391

  Mannocci, Alice ^a   De Feo, Emma ^a   De Waure, Chiara ^a   Specchia, Maria Lucia ^a   Gualano, Maria Rosaria ^a   Barone, Carlo ^a   Ricciardi, Walter ^a   La Torre, Giuseppe ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Beyond progression; Herceptin; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77954963893     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600302     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin, 55: 74-108, 2005.
2. Rapporto sui tumori in Italia anno 2008. Available from: http://www.registri-tumori.it/cms/files/TumoriFemminili-2008Rev.pdf
3. AIOM Guidelines. Available from: www.aiom.it
4. Cainfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9: 606-616, 2004.
5. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11: 318-324, 2006.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177-182, 1987.
7. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer, 63: 434-438, 1991.
8. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res, 284: 31-53, 2003.
9. National Institute for Clinical Excellence (NICE): 2002 Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer, London, England: NICE (Technology Appraisal Guidance no. 34).
10. Clements DM, Holland PA: Metastatic disease of the breast and local recurrence of breast cancer. Surgery, 25: 276-279, 2007.
11. National Institute for Clinical Excellence (NICE). 2001 Guidance on the Use of Taxanes for the Treatment of Breast Cancer, London, England: NICE (Technology Appraisal Guidance no. 30).
12. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353: 1673-1684, 2005.
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353: 1659-1672, 2005. (Pubitemid 41464705)
14. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17: 2639-48, 1999.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ital J Public Health, 6 (4): 94-126, 2009.
16. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer, 4: 120-125, 2003.
17. Suzuki Y, Tokuda Y, Saito Y, Ohta M, Tajima T: Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol, 33: 514-517, 2003.
18. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R: Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer, 5: 52-58, 2004.
19. García-Sáenz JA, Martín M, Puente J, López-Tarruella S, Casado A, Moreno F, Grande E, Díaz-Rubio E: Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer, 6: 325-329, 2005.
20. Bartsch R, Wenzel C, Hussian D, Pluschnig U, Sevelda U, Koestler W, Altorjai G, Locker GJ, Mader R, Zielinski CC, Steger GG: Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer, 6: 63, 2006.
21. Adamo V, Franchina T, Adamo B, Ferraro G, Rossello R, Maugeri Saccà M, Scibilia C, Valerio MR, Russo A: Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol, 18 (Suppl 6): vi11-15, 2007.
22. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol, 25: 3853-3858, 2007.
23. Montemurro F, Viale G, Donadio M, Bottini A, Botti G, dei Tos AP, Danese S, Clavarezza M, Sapino A, Aglietta M: Retrospective evaluation of clinical outcomes in HER2-positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib. Breast Cancer Res Treat, 106 (Suppl 1): S185 (abstr 4057), 2007.
24. Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG: Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients withmetastatic breast cancer. Cancer Chemother Pharmacol, 62: 903-910, 2008.
25. Cancello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G, Plaitano M, De Placido S, De Laurentiis M: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res, 10: R60, 2008.
26. Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F: Do HER-2 positivemetastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? Amono-institutional experience and systematic review of observational studies. Breast, 17: 499-505, 2008.
27. Tokajuk P, Czartoryska-Arlukowicz B, Wojtukiewicz MZ: Continuation of trastuzumab-based therapy beyond disease progression in metastatic breast cancer patients - a retrospective one center analysis. Eur J Cancer, 7(Suppl 6): 221, (abstr 581) 2008.
28. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol, 27: 1999-2006, 2009.
29. Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh FE, Kaufmann M, Loibl S: Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol, 26: (abstr 1025), 2008.
30. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11: 318-324, 2006.
31. Montemurro F, Redana S, Nolè F, Donadio M, Jacomuzzzi ME, Valabrega G, Viale G, Sapino A, Aglietta M: Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer, 8: 209, 2008.
32. Rossello R, Adamo B, Franchina T, Garipoli C, Iorfida M, Festa V, Montalto E, Valerio MR, Russo A, Adamo V: Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer (MBC): a five-year experience. Ann Oncol, 18 (Suppl 11): xi37-xi55 (abstr C26), 2007.
33. Jahanzeb M: Continuing trastuzumab beyond progression. J Clin Oncol, 27: 1935-1937, 2009.
34. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733-4273, 2006.
35. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc Am Soc Clin Oncol, 26: 1015, 2008.
36. La Torre G, Chiaradia G, Mannocci A, de Waure C, Ricciardi W, Capri S, Bamfi F, Bianchi C, Lapinet-Vera J, Marocco a, Patarnello F, Recchia G: Health Technology Assessment of the anti-HPV vaccination. Ital J Public Health, 4(2)(Suppl 1): 1-60, 2009.